D-0539-2020 Class II Ongoing

Recalled by Sanofi-Aventis U.S. LLC — Bridgewater, NJ

FDA drug recall D-0539-2020 was initiated by Sanofi-Aventis U.S. LLC on Oct 22, 2019 and is designated Class II. Reason for recall: CGMP Deviations: Presence of NDMA impurity detected in product. The recall status is ongoing.

Recall details

Product Type
Drugs
Report Date
Dec 11, 2019
Initiation Date
Oct 22, 2019
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Maximum Strength Zantac 150 mg, Distributed by: Chattem, Inc., a Sanofi Company P.O. Box 2219, Chattanooga, TN 37409-0219. NDC's: 0597-0121-01, 0597-0121-06, 0597-0121-08, 0597-0121-09, 0597-0121-11, 0597-0121-24, 0597-0121-38, 0597-0121-50, 0597-0121-64, 0597-0121-66, 0597-0121-68, 0597-0121-78, 0597-0121-80, 0597-0121-82, 0597-0121-85, 0597-0121-90, 0597-0121-94.

Reason for recall

CGMP Deviations: Presence of NDMA impurity detected in product.

Distribution pattern

Nationwide

Code information

all lots

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0539-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0539-2020. Report a data issue: hello@regdatalab.com.